Inhibition of glycolysis or PERK deletion in MDMs reduced these immunosuppressive effects, enhanced T cell infiltration, delayed tumor growth, and improved the effectiveness of 4-1BB (also known as CD137 or TNF receptor superfamily member 9 (TNFRSF9)) based immunotherapy [176]. The gene discussed is EIF2AK3; the disease is neoplasm.